{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:03:15Z","timestamp":1790082195907,"version":"4.0.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005624","name":"Hannover Medical School","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005624","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"German Centre for Infection Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jhepr.2025.101643","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T17:17:46Z","timestamp":1760807866000},"page":"101643","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment response to bulevirtide is linked to amelioration of portal hypertension in patients with chronic hepatitis D"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4425-2640","authenticated-orcid":false,"given":"Lisa","family":"Sandmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2871-4147","authenticated-orcid":false,"given":"Mathias","family":"Jachs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammo L.","family":"Tergast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3398-6120","authenticated-orcid":false,"given":"Lukas","family":"Hartl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1239-6968","authenticated-orcid":false,"given":"Birgit","family":"Bremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin A.","family":"Kabelitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2587-1385","authenticated-orcid":false,"given":"Michael","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9651-5401","authenticated-orcid":false,"given":"Julius F.M.","family":"Egge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6708-3061","authenticated-orcid":false,"given":"Lorenz","family":"Balcar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt Silvester","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine S.","family":"Falk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert Friedrich","family":"St\u00e4ttermayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Cornberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Deterding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Mandorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2906-0480","authenticated-orcid":false,"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4590-3583","authenticated-orcid":false,"given":"Thomas","family":"Reiberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Maasoumy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2025.101643_bib1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies","volume":"44","author":"D'Amico","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101643_bib2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2007.05.024","article-title":"Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis","volume":"133","author":"Ripoll","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2025.101643_bib3","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jhep.2024.03.005","article-title":"Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta","volume":"81","author":"Jachs","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101643_bib4","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/hep.30885","article-title":"Changes in hepatic venous pressure gradient predict hepatic decompensation in patients who achieved sustained virologic response to interferon-free therapy","volume":"71","author":"Mandorfer","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101643_bib5","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jhep.2009.05.031","article-title":"Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension","volume":"51","author":"Manolakopoulos","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101643_bib6","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","article-title":"Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension","volume":"65","author":"Mandorfer","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101643_bib7","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jhep.2020.05.050","article-title":"Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension","volume":"73","author":"Lens","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101643_bib8","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.dld.2022.02.013","article-title":"Angiopoietin 2 levels decrease after HCV-cure and reflect the evolution of portal hypertension","volume":"54","author":"Bauer","year":"2022","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhepr.2025.101643_bib9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/apt.13844","article-title":"Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV\/HCV patients with advanced liver disease","volume":"45","author":"Schwabl","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2025.101643_bib10","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jhep.2022.07.016","article-title":"Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension","volume":"77","author":"Degasperi","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101643_bib11","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.jhep.2022.06.010","article-title":"Bulevirtide with or without pegIFNalpha for patients with compensated chronic hepatitis delta: from clinical trials to real-world studies","volume":"77","author":"Lampertico","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101643_bib12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa2213429","article-title":"A phase 3, randomized trial of bulevirtide in chronic hepatitis D","volume":"389","author":"Wedemeyer","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101643_bib13","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jhep.2024.05.001","article-title":"Bulevirtide monotherapy in patients with chronic HDV: efficacy and safety results through week 96 from a phase III randomized trial","volume":"81","author":"Wedemeyer","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101643_bib14","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII \u2013 renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101643_bib15","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/apt.16945","article-title":"Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a \"real world\" study","volume":"56","author":"Jachs","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2025.101643_bib16","article-title":"Transjugular diagnostic procedures in hepatology: indications, techniques and interpretation","volume":"7","author":"Bettinger","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2025.101643_bib17","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Faculty Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"de Franchis","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101643_bib18","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1056\/NEJMoa044456","article-title":"Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis","volume":"353","author":"Groszmann","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101643_bib19","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","article-title":"Beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial","volume":"393","author":"Villanueva","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2025.101643_bib20","series-title":"R: a language and environment for statistical computing","year":"2018"},{"key":"10.1016\/j.jhepr.2025.101643_bib21","series-title":"ggplot2 \u2013 elegant graphics for data analysis","author":"Wickham","year":"2016"},{"key":"10.1016\/j.jhepr.2025.101643_bib22","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2023.05.001","article-title":"EASL Clinical Practice Guidelines on hepatitis delta virus","volume":"79","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101643_bib23","doi-asserted-by":"crossref","first-page":"e715","DOI":"10.1055\/a-2181-3345","article-title":"Antiviral therapy of chronic hepatitis D virus infection \u2013 addendum to the S3 guideline \"Prophylaxis, diagnosis and therapy of hepatitis B virus infection\" of the German society for gastroenterology, digestive and metabolic diseases (DGVS)","volume":"61","author":"Sandmann","year":"2023","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.jhepr.2025.101643_bib24","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1097\/HEP.0000000000000431","article-title":"Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference","volume":"78","author":"Ghany","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101643_bib25","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1053\/j.gastro.2004.03.017","article-title":"Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis","volume":"126","author":"Farci","year":"2004","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.jhepr.2025.101643_bib26","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/liv.15410","article-title":"Interferon-based treatment of chronic hepatitis D","volume":"43","author":"Sandmann","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2025.101643_bib27","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/hep.28876","article-title":"Antiviral treatment and liver-related complications in hepatitis delta","volume":"65","author":"Wranke","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101643_bib28","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1053\/j.gastro.2017.07.016","article-title":"Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis","volume":"153","author":"Lens","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2025.101643_bib29","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/hep.31462","article-title":"Noninvasive risk stratification after HCV eradication in patients with advanced chronic liver disease","volume":"73","author":"Semmler","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101643_bib30","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/HEP.0000000000001005","article-title":"Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure","volume":"81","author":"Semmler","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101643_bib31","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1177\/2050640618786067","article-title":"Long-term changes in liver elasticity in hepatitis C virus-infected patients with sustained virologic response after treatment with direct-acting antivirals","volume":"6","author":"Pietsch","year":"2018","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.jhepr.2025.101643_bib32","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/liv.13256","article-title":"Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index","volume":"37","author":"Bachofner","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2025.101643_bib33","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1080\/00365521.2018.1481996","article-title":"Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology","volume":"53","author":"Lund Laursen","year":"2018","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhepr.2025.101643_bib34","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2036.2012.05134.x","article-title":"Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis","volume":"36","author":"Gronbaek","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2025.101643_bib35","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3350\/cmh.2024.0587","article-title":"Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis","volume":"31","author":"Tiede","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101643_bib36","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41575-021-00520-7","article-title":"Cirrhosis-associated immune dysfunction","volume":"19","author":"Albillos","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101643_bib37","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/jvh.12947","article-title":"Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy","volume":"25","author":"Lutterkort","year":"2018","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhepr.2025.101643_bib38","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/jvh.13439","article-title":"A transient early HBV-DNA increase during PEG-IFNalpha therapy of hepatitis D indicates loss of infected cells and is associated with HDV-RNA and HBsAg reduction","volume":"28","author":"Anastasiou","year":"2021","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhepr.2025.101643_bib39","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/j.1478-3231.2011.02593.x","article-title":"Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment","volume":"31","author":"Grabowski","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2025.101643_bib40","article-title":"Successful HCV therapy reduces liver disease severity and inflammation biomarkers in HIV\/HCV-coinfected patients with advanced cirrhosis: a cohort study","volume":"8","author":"Medrano","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jhepr.2025.101643_bib41","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28955","article-title":"HCV spontaneous clearers showed low senescence profile in people living with HIV under long ART","volume":"95","author":"Lara-Aguilar","year":"2023","journal-title":"J Med Virol"},{"key":"10.1016\/j.jhepr.2025.101643_bib42","first-page":"84","article-title":"Increased Th1, Th17 and pro-fibrotic responses in hepatitis C-infected patients are down-regulated after 12 weeks of treatment with pegylated interferon plus ribavirin","volume":"21","author":"Jimenez-Sousa","year":"2010","journal-title":"Eur Cytokine Netw"},{"key":"10.1016\/j.jhepr.2025.101643_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105073","article-title":"Remodeling of immunological biomarkers in patients with chronic hepatitis C treated with direct-acting antiviral therapy","volume":"190","author":"Ribeiro","year":"2021","journal-title":"Antivir Res"},{"key":"10.1016\/j.jhepr.2025.101643_bib44","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/liv.12908","article-title":"Determinants of platelet count are different in patients with compensated and decompensated cirrhosis","volume":"36","author":"Latorre","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2025.101643_bib45","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jhep.2020.10.004","article-title":"Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality","volume":"74","author":"Costa","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101643_bib46","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1097\/HEP.0000000000000847","article-title":"Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis \u2013a real-world case series","volume":"80","author":"Dietz-Fricke","year":"2024","journal-title":"Hepatology"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555925003258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555925003258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T19:44:39Z","timestamp":1778096679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555925003258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2589555925003258"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2025.101643","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment response to bulevirtide is linked to amelioration of portal hypertension in patients with chronic hepatitis D","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2025.101643","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101643"}}